Citigroup
ARQT icon

Citigroup’s Arcutis Biotherapeutics ARQT Stock Holding History

Citigroup’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.97M Buy
151,394
+103,057
+213% +$2.4M ﹤0.01% 2344
2026
Q1 		$1.14M Sell
48,337
-6,809
-12% -$174K ﹤0.01% 3032
2025
Q4 		$1.6M Buy
55,146
+9,235
+20% +$236K ﹤0.01% 2807
2025
Q3 		$865K Sell
45,911
-313,511
-87% -$4.94M ﹤0.01% 3251
2025
Q2 		$5.04M Buy
359,422
+57,870
+19% +$811K ﹤0.01% 1883
2025
Q1 		$4.72M Sell
301,552
-25,713
-8% -$362K ﹤0.01% 1947
2024
Q4 		$4.56M Buy
327,265
+237,643
+265% +$2.6M ﹤0.01% 2058
2024
Q3 		$833K Buy
89,622
+35,023
+64% +$346K ﹤0.01% 3405
2024
Q2 		$508K Sell
54,599
-661,841
-92% -$5.99M ﹤0.01% 3385
2024
Q1 		$7.1M Buy
716,440
+703,727
+5,535% +$5.25M ﹤0.01% 1476
2023
Q4 		$41.1K Sell
12,713
-164,109
-93% -$446K ﹤0.01% 4620
2023
Q3 		$939K Buy
176,822
+23,234
+15% +$198K ﹤0.01% 2576
2023
Q2 		$1.46M Sell
153,588
-90,411
-37% -$1M ﹤0.01% 2516
2023
Q1 		$2.68M Buy
243,999
+110,771
+83% +$1.6M ﹤0.01% 1823
2022
Q4 		$1.97M Sell
133,228
-27,273
-17% -$476K ﹤0.01% 2047
2022
Q3 		$3.07M Buy
160,501
+114,683
+250% +$2.6M ﹤0.01% 1843
2022
Q2 		$976K Buy
45,818
+34,215
+295% +$702K ﹤0.01% 2672
2022
Q1 		$223K Sell
11,603
-108,637
-90% -$1.84M ﹤0.01% 4028
2021
Q4 		$2.49M Buy
120,240
+95,304
+382% +$1.9M ﹤0.01% 2437
2021
Q3 		$596K Sell
24,936
-36,483
-59% -$832K ﹤0.01% 3491
2021
Q2 		$1.68M Buy
61,419
+8,087
+15% +$228K ﹤0.01% 2803
2021
Q1 		$1.54M Buy
53,332
+47,904
+883% +$1.5M ﹤0.01% 2666
2020
Q4 		$153K Sell
5,428
-4,456
-45% -$109K ﹤0.01% 5185
2020
Q3 		$290K Buy
9,884
+6,873
+228% +$184K ﹤0.01% 4311
2020
Q2 		$91K Sell
3,011
-3
-0.1% -$87 ﹤0.01% 5650
2020
Q1 		$90K Buy
+3,014
New +$81K ﹤0.01% 5420

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citigroup's ARQT Position: Q2 2026 in Review

Citigroup increased its Arcutis Biotherapeutics (ARQT) stake by 213% in Q2 2026, buying an estimated $2.4M and bringing the position to 151,394 shares worth $3.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2344.

Citigroup first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. The position peaked at $7.1M in Q1 2024. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Citigroup held 151,394 shares of Arcutis Biotherapeutics worth $3.97M as of Q2 2026.
  • Citigroup bought 103,057 Arcutis Biotherapeutics shares in Q2 2026, an estimated $2.4M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2344 holding.
  • Citigroup first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • Citigroup's Arcutis Biotherapeutics position peaked at $7.1M in Q1 2024.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.